Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730046 | PMC |
| http://dx.doi.org/10.1200/PO.23.00287 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sensitivity to ALK-Directed Therapy in Osteosarcoma With an Acquired Rearrangement.
JCO Precis Oncol
September 2023
Department of Internal Medicine, Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.
Cancer Res Commun
May 2022
Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase with genomic and expression changes in many solid tumors. ALK inhibition is first line therapy for lung cancers with alterations, and an effective therapy in other tumor types, but has not been well-studied in prostate cancer. Here, we aim to delineate the role of ALK genomic and expression changes in primary and metastatic prostate cancer.
View Article and Find Full Text PDFImmunotherapy for -Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches.
Cancers (Basel)
March 2021
Division of Medical Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI 48109-5848, USA.
Rearrangements in the Anaplastic Lymphoma Kinase () gene have been implicated in 5-6% of all non-small cell lung cancers. -rearranged non-small cell lung cancers are sensitive to -directed tyrosine kinase inhibitors, but generally resistant to single-agent immune checkpoint inhibitors. Here, we aim to describe the mechanisms of aberrations in non-small cell lung cancer by which an immunosuppressed tumor microenvironment is created, leading to host immune evasion.
View Article and Find Full Text PDFTracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.
JCO Precis Oncol
January 2018
Department of Medicine, Massachusetts General Hospital, Boston, MA.
Purpose: rearrangements predict for sensitivity to ALK tyrosine kinase inhibitors (TKIs). However, responses to ALK TKIs are generally short-lived. Serial molecular analysis is an informative strategy for identifying genetic mediators of resistance.
View Article and Find Full Text PDFPerfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
Clin Cancer Res
November 2014
Medicine (Section of Medical Oncology), Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut.
Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!